Navigation Links
Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
Date:12/10/2009

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's ability to think clearly, relate to others, and distinguish between reality and imagination. In the U.S., approximately 2.4 million Americans have schizophrenia, with men and women affected equally.(1) Non-adherence to medication treatment is a common problem encountered in patients with schizophrenia, which can lead to relapse (an increase in symptoms) and hospitalization.(2) Since both INVEGA SUSTENNA and RISPERDAL CONSTA are given by a healthcare professional, it offers the physician a way to monitor patient medication adherence and intervene when a patient misses a dose. Both products offer flexibility to physicians and patients, based on their dosing regimens, thereby offering an important option to those who may need it.

The objective of this study was to show that INVEGA SUSTENNA was statistically similar (non-inferior) to RISPERDAL CONSTA, as measured by the Positive and Negative Syndrome Scale (PANSS). INVEGA SUSTENNA, a once-monthly injectable atypical antipsychotic, was recently approved in the U.S. for the acute and maintenance treatment of schizophrenia in adults. RISPERDAL CONSTA, the first long-acting injectable atypical antipsychotic, was approved for the treatment of schizophrenia in adults in the U.S. in 2003, and recently was approved for use as maintenance therapy in the treatment of Bipolar I Disorder.

"Physicians need treatment options that match the needs of their patients, particularly when compliance is a significant issue. INVEGA SUSTENN
'/>"/>

SOURCE Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  PENTAX Medical, a healthcare industry ... global leader in ultrasound imaging, recently announced renewed ... enable further innovation in the development of Endoscopic ... systems and PENTAX Medical endoscopic portfolio have formed ... EUS systems. This agreement will continue to grow ...
(Date:5/17/2013)... May 17, 2013  Boston Scientific Corporation (NYSE: ... annual EuroPCR Scientific Program May 21-24 in ... present a particularly rich and diversified set of data ... , M.D., global chief medical officer, Boston Scientific.  ... presented, including the NG PROMUS trial, which evaluated our ...
(Date:5/16/2013)... , May 16, 2013  Today, the National ... Carolina House of Representatives recently approved a ... chemotherapy from charging patients higher out-of-pocket fees for newer, ... many of which have more severe side-effects. However, the ... of $300, which will continue to be a barrier ...
Breaking Medicine Technology:PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... 4, 2011 Bayer HealthCare and the Governor of New ... has selected New Jersey as the new "home" of Bayer ... are very excited about the prospect of having a new ... employees from every division and function under one roof," said ...
... DIEGO, April 4, 2011 AnaBios Corporation, Inc., an innovative ... the assessment of efficacy and safety of drugs, announced today ... dollar raise of a total Series A investment of up ... Coast Angels. Tech Coast Angels, Angel Capital Entrepreneur (ACE) Fund ...
Cached Medicine Technology:Bayer HealthCare Selects the State of New Jersey for East Coast Site Consolidation 2AnaBios Corporation Closes Series A Financing 2
(Date:5/18/2013)... MOOSGO.COM published an original art book for iPad ... group of artists who share their creations based on the ... Exclusively for iPad . , This work gathers ... that reflect the signature idiosyncrasy and passion of tango. Such ... Store and it includes a free trailer of the ...
(Date:5/18/2013)... 2013) There are significant cost and risk ... diagnose or treat gastrointestinal problems, according to research ... A study by New York Presbyterian Hospital and ... may substantially reduce the cost and risk of ... believed to affect nearly 25 percent of adults, ...
(Date:5/18/2013)... In a May 14, 2013 article entitled ... Discovering Cancer Gene,” Fox News reported the movie star ... she carried a gene that doctors estimated gave her ... 50 percent risk of ovarian cancer (go to: goo.gl/5JHBP). ... 2013 with a blog post entitled “A Patient’s Journey: ...
(Date:5/18/2013)... A ground-breaking advance in colonoscopy technology signals ... presented today at Digestive Disease Week (DDW). Additional ... for colonoscopies and exploring safer methods for removing ... a device called a colonoscope to examine the ... a doctor to look for precancerous polyps called ...
(Date:5/18/2013)... York, New York (PRWEB) May 18, 2013 ... Gynecare pelvic mesh products continue to move forward in ... Superior Court, Bernstein Liebhard LLP reports. According to a ... Conference in the Ethicon pelvic mesh litigation will be ... that 2,755 complaints have been filed in the proceeding ...
Breaking Medicine News(10 mins):Health News:New Art Book for iPad: Tango Art 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3
... -- Environmental pollutants such as dioxins, PCBs and pesticides ... to a new study. Atherosclerosis is the major ... common cause of death in industrialized countries, said the ... levels of persistent (long-lived and hard to degrade) organic ...
... have identified cells and signaling molecules that trigger the ... his colleagues report October 10, 2011, online in the ... lung tissue in mice induces smooth muscle cells surrounding ... growth factor 10 (FGF10), which induces surviving epithelial cells ...
... and the Case Comprehensive Cancer Center are proud ... $5.4 million grant to study genetic determinants of ... from the National Cancer Institute will support the ... of multiple centers collaborating to develop an understanding ...
... of selected prescription medications, including antidepressants, antihistamines, bronchodilators, ... of lower urinary tract symptoms among men according ... Archives of Internal Medicine . This ... these selected prescription drugs and LUTS among men ...
... Radiation Oncology (ASTRO), the Association of Residents in Radiation ... Educator of the Year Award. , ARRO sponsors the ... teachers and mentors of radiation oncology residents. Residents from ... select one faculty member from their program for the ...
... Complementary and alternative medical (CAM) treatments such as herbal ... especially among older patients and those with chronic pain. ... potentially harmful side effects when combined with medications prescribed ... in the Journal of the American Academy ...
Cached Medicine News:Health News:Environmental Toxins Linked to Hardening of Arteries 2Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 2Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 3Health News:Common medications can contribute to lower urinary tract symptoms in men 2Health News:ARRO honors 39 with Educator of the Year Award 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 3
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: